Frailty and associated factors in patients with non-Hodgkin lymphoma during chemotherapy: a longitudinal study
Abstract
PurposeTo investigate the dynamic changes of frailty and its associated factors in patients with non-Hodgkin lymphoma during chemotherapy.MethodUsing a convenience sampling method, 266 patients with non-Hodgkin lymphoma hospitalized in the Department of Hematology at five tertiary hospitals in China were recruited from January to August 2025. General information, frailty, cognition, physical performance, nutrition, and anxiety were investigated before chemotherapy (T0), at the third cycle (T1), and at the end of chemotherapy (T2). Generalized Estimating Equations were utilized to analyze the factors related to frailty.ResultsFinally, 252 patients completed the longitudinal follow-up. The mean frailty scores were 4.31 ± 2.46 (T0), 5.22 ± 2.59 (T1), and 4.50 ± 2.65 (T2). Generalized estimating equations results indicated that factors significantly associated with frailty included sociodemographic factors (level of education), treatment-related variables (dose reduction, treatment delay), nutritional and inflammatory factors (appetite loss, lymphocyte count, hemoglobin, C-reactive protein, CONUT score), physical function factors (grip strength, SPPB score), cognitive function (MoCA-B score), and psychological status (GAD-7 score) (P < 0.05).ConclusionsA substantial proportion of patients with non-Hodgkin lymphoma meet criteria for frailty during chemotherapy, with prevalence peaking at 59.3% at the end of the third cycle, and the observed trajectory of initial increase followed by decrease warrants cautious interpretation given the observational design. Dynamic monitoring and individualized supportive care are recommended, though interventional studies are needed to confirm whether frailty can be genuinely modified.
Related
- Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy
- Longitudinal Association Between the Change in Serum Procollagen Type III N-Terminal Peptide (PIIINP) and Skeletal Muscle Loss in Patients with Gastrointestinal Cancer Receiving Chemotherapy: A Prospective Cohort Study
- Heterogeneous trajectories of oral frailty and their determinants in older patients receiving dental implants: a longitudinal study.
- Baseline estimated pulse wave velocity (ePWV) and its longitudinal change are associated with incident frailty in older Chinese adults: a prospective cohort study
- Quality of Life and Patient-Reported Outcomes During First-Line Chemotherapy in Older Patients with De Novo Metastatic Gastrointestinal Cancers: A Prospective Longitudinal Study.
BibTeX
@article{zhang2026frailty,
title = {{Frailty and associated factors in patients with non-Hodgkin lymphoma during chemotherapy: a longitudinal study}},
author = {Ying Zhang and Ruofei Du and Yating Du and Huimin Yang and Yinxia Dou},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1906500},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1906500},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Frailty and associated factors in patients with non-Hodgkin lymphoma during chemotherapy: a longitudinal study
AU - Ying Zhang
AU - Ruofei Du
AU - Yating Du
AU - Huimin Yang
AU - Yinxia Dou
PY - 2026
DA - 2026/11/06
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1906500
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1906500
AB - PurposeTo investigate the dynamic changes of frailty and its associated factors in patients with non-Hodgkin lymphoma during chemotherapy.MethodUsing a convenience sampling method, 266 patients with non-Hodgkin lymphoma hospitalized in the Department of Hematology at five tertiary hospitals in China were recruited from January to August 2025. General information, frailty, cognition, physical performance, nutrition, and anxiety were investigated before chemotherapy (T0), at the third cycle (T1), and at the end of chemotherapy (T2). Generalized Estimating Equations were utilized to analyze the factors related to frailty.ResultsFinally, 252 patients completed the longitudinal follow-up. The mean frailty scores were 4.31 ± 2.46 (T0), 5.22 ± 2.59 (T1), and 4.50 ± 2.65 (T2). Generalized estimating equations results indicated that factors significantly associated with frailty included sociodemographic factors (level of education), treatment-related variables (dose reduction, treatment delay), nutritional and inflammatory factors (appetite loss, lymphocyte count, hemoglobin, C-reactive protein, CONUT score), physical function factors (grip strength, SPPB score), cognitive function (MoCA-B score), and psychological status (GAD-7 score) (P < 0.05).ConclusionsA substantial proportion of patients with non-Hodgkin lymphoma meet criteria for frailty during chemotherapy, with prevalence peaking at 59.3% at the end of the third cycle, and the observed trajectory of initial increase followed by decrease warrants cautious interpretation given the observational design. Dynamic monitoring and individualized supportive care are recommended, though interventional studies are needed to confirm whether frailty can be genuinely modified.
SN - 2234-943X
ER -